clinical trial · NCT05077904
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL·phase3·recruiting·n = 350
Stereotypical Prolonged SeizuresStaccato alprazolamPlacebo
brief summary
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
started
Dec 7, 2021
primary completion
Jul 31, 2026
completion
Jul 31, 2026
last updated
Jul 1, 2026
official title
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol